PMID- 29956212
OWN - NLM
STAT- MEDLINE
DCOM- 20181116
LR  - 20181116
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 1061
DP  - 2018
TI  - Animal Models of Non-alcoholic Fatty Liver Diseases and Its Associated Liver 
      Cancer.
PG  - 139-147
LID - 10.1007/978-981-10-8684-7_11 [doi]
AB  - Non-alcoholic fatty liver disease (NAFLD) is a spectrum of diseases, which 
      include simple liver steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis 
      and hepatocellular carcinoma (HCC). It is a burgeoning health problem worldwide 
      in line with the trend towards unhealthy diet and increased prevalence of obesity 
      and type 2 diabetes mellitus (T2DM). Many animal models that illustrate both the 
      histology and pathology of human NAFLD have been established. It is important to 
      choose an animal model that best conforms to the aim of the study. This chapter 
      presents a critical analysis of the histopathology and pathogenesis of NAFLD and 
      the most commonly used and recently developed animal models of hepatic steatosis, 
      NASH and NAFLD-induced hepatocellular carcinoma (NAFLD-HCC). The main mechanisms 
      involved in the experimental pathogenesis of NAFLD in various animal models were 
      also discussed. This chapter also includes a brief summary of recent therapeutic 
      targets found using animal models. Although current animal models provide 
      important guidance in understanding the pathogenesis and development of NAFLD, 
      future study is essential to develop more precise models that better mimic the 
      disease spectrum for both improved mechanistic understanding and identification 
      of novel therapeutic options.
FAU - Lau, Jennie Ka Ching
AU  - Lau JKC
AD  - Institute of Digestive Disease and Department of Medicine & Therapeutics, State 
      Key Laboratory of Digestive Disease, LKS Institute of Health Sciences, The 
      Chinese University of Hong Kong, Hong Kong, Hong Kong. jennie_lau@outlook.com.
AD  - SHHO College, The Chinese University of Hong Kong, Hong Kong, Hong Kong. 
      jennie_lau@outlook.com.
FAU - Zhang, Xiang
AU  - Zhang X
AD  - Institute of Digestive Disease and Department of Medicine & Therapeutics, State 
      Key Laboratory of Digestive Disease, LKS Institute of Health Sciences, The 
      Chinese University of Hong Kong, Hong Kong, Hong Kong.
FAU - Yu, Jun
AU  - Yu J
AD  - Institute of Digestive Disease and Department of Medicine & Therapeutics, State 
      Key Laboratory of Digestive Disease, LKS Institute of Health Sciences, The 
      Chinese University of Hong Kong, Hong Kong, Hong Kong.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
SB  - IM
MH  - Animals
MH  - Carcinoma, Hepatocellular/genetics/*metabolism/pathology
MH  - Diabetes Mellitus, Type 2/genetics/*metabolism/pathology
MH  - Humans
MH  - Liver Cirrhosis/genetics/*metabolism/pathology
MH  - Liver Neoplasms, Experimental/genetics/*metabolism/pathology
MH  - Non-alcoholic Fatty Liver Disease/genetics/*metabolism/pathology
MH  - Obesity/genetics/*metabolism/pathology
OTO - NOTNLM
OT  - Dietary animal model
OT  - Disease histopathology
OT  - Genetic animal model
OT  - Liver cancer
OT  - Non-alcoholic fatty liver disease (NAFLD)
EDAT- 2018/06/30 06:00
MHDA- 2018/11/18 06:00
CRDT- 2018/06/30 06:00
PHST- 2018/06/30 06:00 [entrez]
PHST- 2018/06/30 06:00 [pubmed]
PHST- 2018/11/18 06:00 [medline]
AID - 10.1007/978-981-10-8684-7_11 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2018;1061:139-147. doi: 10.1007/978-981-10-8684-7_11.